Quoin Pharmaceuticals Ltd DRC (QNRX) - Total Assets
Based on the latest financial reports, Quoin Pharmaceuticals Ltd DRC (QNRX) holds total assets worth $15.69 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Quoin Pharmaceuticals Ltd DRC to assess how comfortably operating cash covers total debt obligations.
Quoin Pharmaceuticals Ltd DRC - Total Assets Trend (2015–2025)
This chart illustrates how Quoin Pharmaceuticals Ltd DRC's total assets have evolved over time, based on quarterly financial data. See Quoin Pharmaceuticals Ltd DRC (QNRX) net assets for net asset value and shareholders' equity analysis.
Quoin Pharmaceuticals Ltd DRC - Asset Composition Analysis
Current Asset Composition (December 2025)
Quoin Pharmaceuticals Ltd DRC's total assets of $15.69 Million consist of 98.1% current assets and 1.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18724.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $383.33 Million | 1880.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Quoin Pharmaceuticals Ltd DRC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see QNRX market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Quoin Pharmaceuticals Ltd DRC's current assets represent 98.1% of total assets in 2025, an increase from 91.0% in 2015.
- Cash Position: Cash and equivalents constituted 18724.8% of total assets in 2025, up from 29.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1879.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 1880.0% of total assets.
Quoin Pharmaceuticals Ltd DRC Competitors by Total Assets
Key competitors of Quoin Pharmaceuticals Ltd DRC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Quoin Pharmaceuticals Ltd DRC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.87 | 2.57 | 0.15 |
| Quick Ratio | 2.87 | 2.57 | 0.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $9.99 Million | $7.64 Million | $-11.09 Million |
Quoin Pharmaceuticals Ltd DRC - Advanced Valuation Insights
This section examines the relationship between Quoin Pharmaceuticals Ltd DRC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.05 |
| Latest Market Cap to Assets Ratio | 0.44 |
| Asset Growth Rate (YoY) | 29.8% |
| Total Assets | $20.39 Million |
| Market Capitalization | $8.94 Million USD |
Valuation Analysis
Below Book Valuation: The market values Quoin Pharmaceuticals Ltd DRC's assets below their book value (0.44x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Quoin Pharmaceuticals Ltd DRC's assets grew by 29.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Quoin Pharmaceuticals Ltd DRC (2015–2025)
The table below shows the annual total assets of Quoin Pharmaceuticals Ltd DRC from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $20.39 Million | +29.80% |
| 2024-12-31 | $15.71 Million | +29.09% |
| 2023-12-31 | $12.17 Million | -15.83% |
| 2022-12-31 | $14.46 Million | +54.52% |
| 2021-12-31 | $9.36 Million | +579.11% |
| 2020-12-31 | $1.38 Million | -77.68% |
| 2019-12-31 | $6.17 Million | +11.76% |
| 2018-12-31 | $5.52 Million | -36.87% |
| 2017-12-31 | $8.75 Million | -0.70% |
| 2016-12-31 | $8.81 Million | +156.59% |
| 2015-12-31 | $3.43 Million | -- |
About Quoin Pharmaceuticals Ltd DRC
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrom… Read more